US EditionStapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial
5 Articles
5 Articles
Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial
Seasonal allergic rhinitis (SAR) places a significant socioeconomic burden, particularly on individuals with poorly managed recurrent and severe symptoms despite standard-of-care treatment. Stapokibart, a humanized monoclonal antibody that targets the interleukin (IL)-4 receptor subunit alpha, inhibits its interaction with both IL-4 and IL-13 in type 2 inflammation. Here we aim to assess the efficacy and safety of stapokibart as an add-on therap…
Laotian Times
The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine
CHENGDU, China, April 6, 2025 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) (“Keymed” or the “Company”) today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα antibody stapokibart, for the treatment of moderate-to-severe seasonal allergic rhinitis (SAR). The study, led by Professor Luo Zhang […]
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
